反应详情

To N-[4′-methyl-2-(morpholin-4-ylcarbonyl)-4,5′-bi-1,3-thiazol-2′-yl]-1H-imidazole-1-carboxamide, prepared as in Step 3 of Example 36, described above (75 mg; 0.19 mmol; 1 eq.) is added DMF (3 ml), glycine dimethylamide acetate (Chem-Impex) (30.1 mg; 0.19 mmol; 1 eq.) and triethylamine (57 μl; 0.41 mmol; 2.20 eq.). The mixture is stirred 3 hours at rt. Solvents are evaporated and the crude product is crystallized in MeOH, affording Compound (46) as a light yellow solid (49 mg; 60%). 1H NMR (DMSO-d6, 300 MHz) δ 2.44 (s, 3H), 2.86 (s, 3H), 2.94 (s, 3H), 3.68 (m, 6H), 4.01 (m, 2H), 4.33 (m, 2H), 6.83 (m, 1H), 7.91 (s, 1H), 10.70 (br s, 1H). M− (ESI): 437.15; M+ (ESI): 439.09. HPLC (method A), Rt: 2.30 min (purity: 99%).

1. customSolvents are evaporated
2. customthe crude product is crystallized in MeOH